Source and publication year | Year of Study | Study Design | No. of patients | No. of neuropathic incidence |
Ribas A. et al. | 2015 | randomized phase 2 trial | N = 178 (pembrolizumab 2 mg/kg) N = 179 (pembrolizumab 10 mg/kg) | N = 2 N = 1 |
James et al. | 2017 | Review | N = 3763 (nivolumab with or without ipilimumab) | N = 22 |
Tomohiro et al. | 2017 | randomized controlled trials-metanalysis | N = 3450 (single-agent PD-1/PD-L1 inhibitor or chemotherapy) | N = 6 |
Paolo et. al | 2017 | randomized, double-blind, multicenter, phase 3 study | N = 364 (ipilimumab 10 mg/kg or 3 mg/kg) | N = 3 |
Antonia et al. | 2016 | Multicenter, open-label, two-stage, multi-arm phase 1/2 trial. | N = 54 (nivolumab 3 mg/kg plus ipilimumab 1 mg/kg) | N = 1 |
Weber JS et. al | 2015 | randomized, open-label, phase 2 study, | N = 68 (Nivolumab followed by ipilimumab) | N = 1 |